- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01948583
Humectant Activity of a New Formulation of Gynomunal® Vaginalgel (GYNOMUNAL®)
Humectant Activity of a New Formulation of Gynomunal® Vaginalgel: Crossover Test Use Versus Previous Formula
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomized, controlled, crossover clinical study; the subjects will use both formulations with an interval of 1 week (wash out period), in reversed sequence according to the treatment arm assigned at each subject during the basal visit.
Both tested products will be applied in the vagina, using the dedicated applicator, once a day, preferably at bedtime. To investigate the activity of the products under study, 4 visits will be performed: a baseline visit (T0), a visit at the end of the first week-treatment (T1), a visit at the end of the wash out period (T2) and a final visit at the end of the second week-treatment (T3).
Volunteers will be asked to follow their normal life and sexual habits, except for not having sexual intercourse 48 hours prior to each examination.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
MB
-
Monza, MB, Italy, 20900
- DermIng S.r.l
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Caucasian healthy female subjects,
- complaining vaginal dryness,
- women in menopause since at least 2 years; the starting period of menopause being defined as the date when the last menstruation or metrorragia linked to hormonal unbalance took place,
- women who agree not to start a replacement therapy during the whole duration of the study,
- women who do not present any active cutaneous pathology of external and internal genitalia,
- women who did not receive any drug or cosmetic treatment on their genitalia during the 2 months preceding the trial,
- women who did not apply vaginal products within at least 1 month before the inclusion in the study,
- women who accept to use only the products authorised by the protocol,
- women who accept not to undertake any treatment for internal and external genitalia during the trial,
- women who did not use, phytoestrogenes based products on treated areas less than 4 weeks before inclusion time,
- women accepting to sign the Informed consent form,
- women able to read the material dedicated to volunteers, to abide by the rules of the protocol and ready to accept its constraints
Exclusion Criteria:
- Volunteers not fulfilling inclusion criteria,
- severe symptoms of vaginal dryness, associated with mucosal signs
- history of intolerance to a vaginal product,
- concomitant participation to another trial,
- refusal to sign the Informed Consent form,
- known allergy to one or several ingredients of the product on trial,
- change in the normal habits in the last 3 months,
- participation in a similar study during the previous 3 months,
- whose insufficient adhesion to the study protocol is foreseeable
- women who start a replacement therapy during the trial
- women who experience during the study the occurrence of any foreseeable risk to use daily the product on trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I: vaginal gel new formulation
Application once a day at evening during the first study week of the vaginal gel new formulation (hyaluronic acid). One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal gel on the market (hyaluronic acid). |
Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
Other Names:
|
Active Comparator: Arm II: vaginal gel on the market
Application once a day at evening during the first study week of the vaginal gel on the market (hyaluronic acid). One week of wash-out (second week). Application once a day at evening during the third study week of the vaginal new formulation (hyluronic acid). |
Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Vaginal Humidity determination
Time Frame: 2 weeks
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tolerability assessment
Time Frame: 2 weeks
|
2 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Adele Sparavigna, Physician, DermIng SRL
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- E0513
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menopause
-
Riphah International UniversityCompleted
-
Englewood Hospital and Medical CenterNanohealth, Inc.WithdrawnMenopause SymptomsUnited States
-
Englewood Hospital and Medical CenterNanohealth, Inc.CompletedMenopause SymptomsUnited States
-
University of Colorado, DenverCompletedMenopause | Pre-menopauseUnited States
-
S.LAB (SOLOWAYS)Center of New Medical TechnologiesCompletedMenopause SymptomsRussian Federation
-
BHR Pharma, LLCTerminatedMenopause Related ConditionsGermany
-
Singapore General HospitalRecruitingMenopause | Menopause Related ConditionsSingapore
-
University of ArkansasRecruitingMenopause Related ConditionsUnited States
-
Wake Forest University Health SciencesWithdrawnMenopause Related Conditions
-
I.M. Sechenov First Moscow State Medical UniversityCompletedMenopause Related ConditionsRussian Federation
Clinical Trials on Hyaluronic Acid
-
Ayhman Al AfifNova Scotia Health AuthorityCompletedHead and Neck Neoplasms | Laryngeal Cancer | Head and Neck Squamous Cell Carcinoma | Voice Disorders
-
Herbarium Laboratorio Botanico LtdaCompletedVaginal Disease | Atrophic VaginitisBrazil
-
Taipei Medical UniversityShin Kong Wu Ho-Su Memorial HospitalUnknown
-
Bioventus LLCTerminatedKnee OsteoarthritisFrance, Monaco
-
Medical University of ViennaRecruiting
-
Tedec-Meiji Farma, S.A.CompletedOsteoarthritis of the KneeSpain
-
Federico II UniversityRecruiting
-
Hawler Medical UniversityCompleted
-
KLSMC Stem Cells, Inc.CompletedArticular Cartilage Disorder of Knee | Articular Cartilage; DegenerationUnited States, Malaysia
-
South China Research Center for Stem Cell and Regenerative...UnknownSenescence Wrinkles, Acne, Pitting Scar